Ajanta Signs Biocon Deal to Market Semaglutide in 26 Countries

Diabetes care is a fast developing segment where GLP-1 based therapies are significantly accepted across the world. In this regard, Ajanta Pharma Ltd., a specialty pharmaceutical formulation business, declared an in-licensing arrangement with Biocon Ltd. on Semaglutide, which is a GLP-1 receptor agonist.

According to the agreement, Biocon will sell Semaglutide to Ajanta, which will market it exclusively in 23 countries and semi-exclusively in three countries in Africa, the Middle East, and Central Asia. The treatment is meant to advance glycaemic regulation in adults, with most of the product patents expiring by March 2026 in most of these markets. When the product gets regulatory approval, which is expected by the end of 2026 or early 2027, Ajanta will commercialize it.

Also Read: India's Rare Disease Shift Driven by PRIP and PLI Policies

Ajanta has established a good branded generic business in over 30 countries with a therapeutic focus in cardiology, antidiabetic, Ophthalmology, Antimalarial, Pain, Gynaecology, paediatric and general health.

Commenting on the agreement, Yogesh Agrawal, Managing Director of Ajanta Pharma Ltd., said, “GLP-1 therapies have seen rapid global acceptance and have emerged as blockbuster products worldwide. We are excited to partner with Biocon for Semaglutide and take this important therapy to the markets where Ajanta has a strong on-ground presence and deep reach. We are confident of building Semaglutide into a meaningful and high-growth brand across these countries in the years ahead.”

Siddharth Mittal, CEO and MD of Biocon Ltd., said, “This partnership with Ajanta Pharma is a strategic step in expanding the global footprint of Biocon’s GLP-1 portfolio and maximizing the value of our scientific investments.”

The partnership is likely to increase access to patients, develop therapeutic leadership of Ajanta and improve the presence of both companies in new pharmaceutical markets.